ABPI

News and analysis related to the Association of the British Pharmaceutical Industry (ABPI).

News and analysis related to the Association of the British Pharmaceutical Industry (ABPI).

UK highlights life sciences’ key role in post-COVID recovery

The UK government used the Queen’s Speech to set out its ambition to make the country a leader

Share

X

UK highlights life sciences’ key role in post-COVID recovery

https://pharmaphorum.com/news/uk-highlights-life-sciences-key-role-in-post-covid-recovery/

Creating a global life sciences superpower from the lessons of COVID

It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry

Share

X

Creating a global life sciences superpower from the lessons of COVID

https://pharmaphorum.com/views-and-analysis/creating-a-global-life-sciences-superpower-from-the-lessons-of-covid-uk/

NICE methods and process review aims to create fertile ground for innovation

The way NICE reviews new medicines is about to go through its biggest change in years – but

Share

X

NICE methods and process review aims to create fertile ground for innovation

https://pharmaphorum.com/views-and-analysis/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation/

Cancer services should be rebuilt after COVID disruption, experts say

There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic,

Share

X

Cancer services should be rebuilt after COVID disruption, experts say

https://pharmaphorum.com/news/cancer-services-should-be-rebuilt-after-covid-19-disruption-report/

Stay calm and carry on: How to implement the updated ABPI code

Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to

Share

X

Stay calm and carry on: How to implement the updated ABPI code

https://pharmaphorum.com/views-analysis-market-access/how-to-implement-the-updated-abpi-code/

VPAS: Progress two years in and opportunities to improve over next three years

In the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and

Share

X

VPAS: Progress two years in and opportunities to improve over next three years

https://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/

VPAS: Achievement so far on objectives for the economy and innovation

In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and

Share

X

VPAS: Achievement so far on objectives for the economy and innovation

https://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-the-economy-and-innovation/

VPAS: Achievements so far on affordability

In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing

Share

X

VPAS: Achievements so far on affordability

https://pharmaphorum.com/views-analysis-market-access/vpas-achievements-so-far-on-affordability/

VPAS: Achievement so far on objectives for patients

The UK has a voluntary agreement that was struck by the government and NHS England (now referred to

Share

X

VPAS: Achievement so far on objectives for patients

https://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-patients/